 "Hetero recalls a batch of its remdesivir brand Covifor after side effects")
Hyderabad-based pharma company Hetero has recalled a batch of its remdesivir brand Covifor after some patients in Raigad district of Maharashtra developed side effects like fever and chills after being administered the drug.
In a letter dated April 29, Hetero Healthcare Director N Bose asked all hospitals, institutions, and stockists to withhold and not use Covifor batch no HCL21013 supplied from the company’s C&F agents due to technical reasons until further instructions. Maharashtra’s Foods & Drugs Administration Minister Rajendra Shingane had said around 90 patients in Raigad district of Maharashtra, who were administered remdesivir doses of a particular brand, developed severe side effects.
Following this, the state government had imposed a temporary suspension on its use. Patients developed chills and fever which were addressed by the district medical authorities. The patients are stable now, Shingane had said. He could not be reached for a comment. Hetero said the company decided to recall the batch as a precautionary measure.
The batch was distributed in Maharashtra and no other incident has come to the company’s notice, it said.
In a letter dated April 29, Hetero Healthcare Director N Bose asked all hospitals, institutions, and stockists to withhold and not use Covifor batch no HCL21013 supplied from the company’s C&F agents due to technical reasons until further instructions. Maharashtra’s Foods & Drugs Administration Minister Rajendra Shingane had said around 90 patients in Raigad district of Maharashtra, who were administered remdesivir doses of a particular brand, developed severe side effects.
Following this, the state government had imposed a temporary suspension on its use. Patients developed chills and fever which were addressed by the district medical authorities. The patients are stable now, Shingane had said. He could not be reached for a comment. Hetero said the company decided to recall the batch as a precautionary measure.
The batch was distributed in Maharashtra and no other incident has come to the company’s notice, it said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%